Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

AŽAndrius ŽučenkaLKLukas KevličiusGDGuoda Daukėlaitė

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high response rates in FLT3-mutated AML patients treated with hypomethylating agents and venetoclax, suggesting effective therapy options.

Key Points

  • This study aims to evaluate the effectiveness of combining hypomethylating agents with venetoclax for treating FLT3-mutated AML.
  • Conducted a retrospective, single-center study
  • Involved patients older than 18 with FLT3-mutated AML
  • Utilized three different remission induction regimens: AzaVenGilt, DecVenGilt, ACTIVE+Gilt
  • Enrolled 39 patients with a 95% overall response rate
  • 82% achieved complete remission or complete remission with incomplete blood count recovery
  • Median overall survival of 24.9 months for all patients

Cite This Study

Žučenka et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3b9https://doi.org/10.1182/blood-2025-1679
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation2025 · 2 citations
  2. 2Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations
  3. 3Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3 -mutated AML2026 · 2 citations
  4. 4Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience2026
  5. 5Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia2024 · 5 citations